Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, November 2000, p. 920-924, Vol. 7, No. 6
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Measurement of Cytokine Secretion, Intracellular Protein
Expression, and mRNA in Resting and Stimulated Peripheral Blood
Mononuclear Cells
Kathleen E.
Sullivan,*
Joie
Cutilli,
Lisa M.
Piliero,
Darlene
Ghavimi-Alagha,
Stuart E.
Starr,
Donald E.
Campbell, and
Steven D.
Douglas
Division of Immunologic and Infectious
Diseases, The Children's Hospital of Philadelphia, Philadelphia,
Pennsylvania
Received 25 February 2000/Returned for modification 25 May
2000/Accepted 13 August 2000
 |
ABSTRACT |
Quantitation of cytokine production is a valuable adjunct to
standard immunologic assays in defining several pathologic processes. Nevertheless, there is little agreement about which tissues should be
assayed, which type of assay should be performed, and which stimulation
protocol should be used. As these types of assays enter the clinical
arena, there is need for standardization. There is also a need to
maximize the amount of information which may be derived from a single
sample. We compared secreted interleukin 4 (IL-4), IL-2, IL-6, tumor
necrosis factor alpha (TNF-
), and gamma interferon proteins as
measured by enzyme-linked immunosorbent assay with intracellular
cytokine production (IL-2 and gamma interferon) as detected by flow
cytometry and quantitative competitive PCR for IL-2, IL-4, TNF-
, and
gamma interferon mRNA and cDNA. Results from unstimulated cells and
cells stimulated with phorbol myristate acetate, phytohemagglutinin,
and phorbol myristate acetate plus phytohemagglutin were compared. All
three methodologies detected significant stimulation of cytokine
production. The combination of phytohemagglutinin and phorbol myristate
acetate was overall the most-potent stimulus.
 |
INTRODUCTION |
Measurement of cytokine levels has
yielded useful information on the pathologic process in different
disease states such as Crohn's disease and rheumatoid arthritis
(9, 18). It may also be of use in the monitoring of disease
progression and/or inflammation. For example, studies suggest that
changes in cytokine production in sepsis and human immunodeficiency
virus (HIV) can predict outcome (11, 15, 20, 22, 25).
Cytokines may be measured in the serum or plasma, in diseased tissues,
or in peripheral blood mononuclear cell (PBMC) preparations (4,
10, 17). Each of these strategies has advantages. Detection of
cytokines in the serum of patients with sepsis, burns, or HIV has led
to a better understanding of the inflammatory component of the host response in these settings (7, 11, 20, 22, 26). While obtaining and storing serum is technically simple, the detection of
cytokines in serum has two major limitations. Cytokines often circulate
as proteins bound to soluble receptors, carrier proteins, or
inhibitors, which may mask their easy detection by enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay (5, 23). Many cytokines are undetectable in serum because they are produced locally and have a very short half-life. In order to circumvent these
significant limitations, cytokine production is often measured in
affected tissues or PBMCs. Affected tissue often requires a biopsy and
may be difficult to obtain, and controls are generally not available.
Therefore, while affected tissue cytokine detection is theoretically
optimal, there are significant practical limitations. This study
utilized PBMCs and measured cytokine production by three different
strategies. As cytokine detection becomes increasingly popular, it will
be important to define the relative limitations and strengths of these
different methodologies. This study explores the potential of using a
single stimulation protocol for PBMCs from which multiple assays could
be run. This is an important first step in the process of standardizing
these assays so that data from different laboratories may be compared.
Three common cytokine detection strategies were utilized in this study.
Each offers its own advantages and disadvantages. The detection of
secreted cytokine protein is by far the most widely used type of
analysis. Because secreted protein is the biologically relevant moiety,
its detection is the closest possible representation of what the cells
are responding to. Secreted protein is typically measured by ELISA or
radioimmunoassay due to the simplicity and sensitivity of these
methods. Bioassays are available for some cytokines (16),
and they have the advantage of being able to distinguish active
cytokines from inactive cytokines, such as is seen with transforming
growth factor
or when some cytokines are complexed with soluble receptors.
The detection of intracellular cytokines is a relatively new technique
in which cells are permeabilized and antibodies are used to detect
cytokine protein within cells by flow cytometry (17, 19,
20). This methodology does not provide exact quantitation of
cytokines but has the advantage of being able to identify which specific cells are producing the cytokine of interest.
Finally, the detection of cytokine messenger RNA has been used in a
number of different settings (3, 6, 8, 12, 21). The use of
PCR greatly increases the sensitivity of detection and has been used
much more widely than Northern blots or RNase protection assays.
Unfortunately PCR is not inherently quantitative. Two main strategies
have been used to try to circumvent this problem. In the first
strategy, the cytokine cDNA is amplified simultaneously with a cDNA
target that is thought to be relatively constant in all cells.
Typically this is actin or ribosomal cDNA. When proper controls have
been performed and both targets are measured during log-phase
amplification, this technique allows relative quantitation of the
cytokine message (3). Generally, fivefold or greater changes
between a test sample and a control can be detected. Because this is a
relative quantitation technique, this methodology is generally not
comparable from laboratory to laboratory. A more quantitative method is
to spike each cytokine amplification mixture with a mimic that is
coamplified by the same primers but generates an amplimer of a slightly
different length. Because the amount of mimic spiked into each tube is
known and the primers are in direct competition for both targets, one
can directly quantitate the amount of cytokine target in each
amplification by comparison with the amount of mimic (3, 21,
24). This technique has the advantage of producing true
quantitation but is hampered by technical difficulty. The mimics for
the cytokine targets are not widely available, and all PCR
methodologies are hindered by the inefficiency of reverse
transcription, RNA degradation, and PCR cross-contamination.
Nevertheless, the use of mimics would seem to offer significant
advantages, and the sensitivity of PCR over other methodologies
represents an attractive option.
 |
MATERIALS AND METHODS |
Subject recruitment.
Healthy adult controls (20 to 52 years
old) were recruited locally. Informed consent was obtained. The
Institutional Review Board of our institution has approved this study.
Blood was obtained and used within 24 h. Sixteen donors were used
for the detection of secreted protein, 6 donors were used for the
detection of intracellular protein, and 18 donors were used for the
detection of cytokine cDNA. The same assays were not always performed
using the same donor, and therefore, comparative analyses are not possible.
Stimulation.
Peripheral blood mononuclear cells were
prepared using Ficoll-Paque (Amersham Pharmacia Biotech, Arlington
Heights, Ill.) and resuspended in RPMI 1640 medium (Gibco BRL, Grand
Island, N.Y.) with 10% fetal bovine serum. A total of 2 × 106 cells in 1 ml of medium were incubated for 48 h
for each stimulation protocol for ELISA analysis, and 106
cells were incubated for either 4 or 24 h for each stimulation protocol for RNA analysis. Cells were incubated for 16 h with monensin for analysis of intracellular cytokines. A total of
106 cells in 1 ml of medium was used for each intracellular
cytokine assay. Phorbol myristate acetate (PMA) (Sigma, St. Louis, Mo.) was used at a final concentration of 25 ng/ml for ELISA and RNA analysis and at 100 ng/ml for intracellular cytokine analysis. Phytohemagglutinin (PHA) (Sigma) was used at a final concentration of 2 µg/ml for ELISA and RNA analysis and 10 µg/ml for intracellular cytokine analysis. Monensin (PharMingen, San Diego, Calif.) was added
to the cultures at the time of stimulation for the intracellular cytokine analysis at a final concentration of 2 µM.
Detection.
Cell culture supernatants were harvested and
stored frozen (
70°C). ELISAs for interleukin 2 (IL-2), IL-4, IL-6,
tumor necrosis factor alpha (TNF-
), and gamma interferon (IFN-
)
were performed on triplicate wells according to the manufacturer's
instructions (Endogen, Woburn, Mass.). Studies have shown that ELISAs
are generally reproducible, with a typical interassay variation of
approximately 50% (1).
Staining and flow cytometry for intracellular IL-2 and IFN-
were
performed according to the manufacturer's protocol (PharMingen). Cells
were simultaneously stained for cychrome-conjugated anti-CD3 and
phycoerytherin-conjugated anti-CD45RO. Isotype controls were run with
each set of samples and were used to define negative and positive cell
populations. Once stained, the cells were permeabilized and fixed, and
either fluorescein-conjugated anti-IL-2 or fluorescein-conjugated anti-IFN-
antibodies (PharMingen) were added. The cells were stained
according to the manufacturer's recommendations and were analyzed by
flow cytometry. A Beckman-Coulter Epics ELITE flow cytometer was used.
Gates on physical parameters and cychrome staining were integrated for
the measurement of both cell surface CD45RO and intracellular cytokine
(IL-2 or IFN-
) staining. A total of 5,000 events were recorded for
each assay.
RNA was prepared using TriReagent (Molecular Research Center,
Cincinnati, Ohio), and cDNA was prepared by reverse transcription
of
RNA by avian myeloblastosis virus reverse transcriptase using
oligo(dT)
primers (Boehringer Mannheim, Indianapolis, Ind.). cDNA
equivalent to
5 × 10
4 cells was used per amplification. Mimics and
primers for IL-2,
IL-4, TNF-

, and IFN-

were obtained from
Clontech (Palo Alto,
Calif.) and used in a standard dilution series
with 40 cycles
of amplification according to the suggested protocol.
Quantitation
was performed by comparison of the cDNA target and mimic
amplimers
according to the manufacturer's recommendation. The lower
limit
of detection was generally 5 × 10
5 amol per
10
4 cells.
Statistics.
The Wilcoxon test was used to compare results
from unstimulated cells with the three stimulation groups. Data were
treated as unpaired, and a two-tailed P value is reported.
Data points which fell below the lower limit of detection for PCR were
not included.
 |
RESULTS |
Unstimulated cells produced secreted cytokine proteins at very low
levels (Table 1). IL-4 production was the
most difficult to induce, and maximal stimulation with PMA and PHA
resulted in a mean concentration of only 68 pg/ml. For all four
cytokines, the optimal stimulus was the combination of PMA and
PHA. IL-4 production was induced 34-fold compared to unstimulated
cells, IL-2 was induced 49-fold compared to unstimulated cells,
IL-6 was induced 22-fold compared to unstimulated cells, IFN-
was induced 91-fold compared to unstimulated cells, and TNF-
was induced 75-fold compared to unstimulated cells. PMA resulted in less
stimulation than PHA for each cytokine with the exception of TNF-
.
When data were analyzed as paired sets, there was no correlation
between reduced production of one cytokine and any other, nor was there
any association between reduced response to one stimulus and reduced
response to another stimulus. The secreted protein production from the
dual stimulated cells (PHA and PMA) was significantly different than
the protein production by the unstimulated cells for all five
cytokines, with P values of <0.001 in all cases. The
differences between PHA stimulation and dual stimulation ranged from
not significant (IL-6 and IL-4) to moderately significant, with
P = 0.05 (IFN-
) and P = 0.01 (TNF-
), to very significant with P = 0.0001 (IL-2).
Intracellular cytokine staining was used to define the percent of total
T cells (detected by anti-CD3 staining) producing IL-2 and IFN-
.
IFN-
was not significantly induced by PHA, but all other stimulation
protocols resulted in increased numbers of cells producing both
cytokines (Fig. 1). For both IL-2 and IFN-
, the combination of PMA and PHA was markedly more
effective than either one alone, and PMA was superior to PHA. This
methodology can be coupled with membrane staining for cell surface
molecules to define mononuclear cell subsets. Because the large
variation between individuals may represent variations in the cellular
constituents of the mononuclear cells, cytokine production within the
CD3+ CD45RO+ and CD3+
CD45RO
T-cell subsets (i.e., memory phenotype and naive
phenotype) were defined. The results from six donors are shown in Fig.
2. Here, the induction of both cytokines
was most pronounced with the combination of PHA and PMA. In fact, there
is significant synergy when both PHA and PMA are used. For
example, IL-2-expressing cells within the CD3+
CD45RO
T-cell subset (these cells were independently
shown to be >95% CD3+ CD45RA+)
constituted 0.3% of the unstimulated cells, 1.3% of the
PHA-stimulated cells, 1.6% of the PMA-stimulated cells, and 13.9% of
the PHA- and PMA- (dually) stimulated cells. Comparing the
PHA-stimulated and the PMA-stimulated with the dually stimulated
cells gave P values of 0.002 and 0.002. IL-2 expressing
cells within the CD3+ CD45RO+ T-cell
subset constituted 0.8% of the unstimulated cells, 2.2% of the
PHA-stimulated cells, 3.4% of the PMA-stimulated cells, and 17.2% of
the dually stimulated cells. Comparing the PHA-stimulated and the
PMA-stimulated with the dually stimulated cells gave P values of 0.004, and 0.009, respectively. IFN-
expressing cells within the CD3+/CD45RO
T cell subset
constituted 0.9% of the unstimulated cells, 1.1% of the PHA
stimulated cells, 3.4% of the PMA-stimulated cells, and 7.1% of the
PHA and PMA dually stimulated cells. Comparing the PHA-stimulated and
the PMA-stimulated with the dually stimulated cells gave P
values of 0.009, and 0.485. IFN-
-expressing cells within the
CD3+ CD45RO+ T-cell subset constituted 1.8% of
the unstimulated cells, 3.1% of the PHA-stimulated cells, 6.9% of the
PMA-stimulated cells, and 28.4% of the dually stimulated cells.
Comparing the PHA-stimulated and the PMA-stimulated with the dually
stimulated cells gave P values of <0.001 and 0.002.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 1.
Intracellular cytokine detection in total T cells.
Comparison of IL-2 (A)- and IFN- (B)-producing cells from PBMC
cultures stimulated with PHA, PMA, or PHA plus PMA. The total T-cell
population was detected by anti-CD3 staining, and the percentage of
total T cells producing either IL-2 or IFN- was determined
(n = 6). Error bars, standard deviations.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
Intracellular cytokine detection in T-cell subsets.
Comparison of IL-2 (A and B)- and IFN- (C and D)-producing cells
from CD3+ CD45RO+ (B and D) and
CD3+ CD45RO (A and C) populations
(n = 6). Error bars, standard deviations.
|
|
Cytokine cDNA was quantitated using a competitive quantitative PCR
method. Two time points were analyzed and the three stimulation protocols were evaluated (Table 2).
Again, IL-4 expression was the most difficult to induce. At 4 h,
IL-2 message was increased 25-fold in the dually stimulated cells
compared to controls, IL-4 was not induced, IFN-
was induced 50-fold
over in the dually stimulated cells compared to controls, and TNF-
was induced 350-fold in the dually stimulated cells compared to the
unstimulated controls. At the 24-h time point, IL-2 message was 10-fold
increased in the dually stimulated cells compared to controls, IL-4 was
induced 1.5-fold over the unstimulated controls, IFN-
was induced
10-fold over the dually stimulated cells compared to controls, and
TNF-
was induced 40-fold in the dually stimulated cells compared to the unstimulated controls. These results are approximately in accordance with what was seen for secreted protein production. Direct
comparison of results is not possible because different donors were
used and there are significant interdonor differences in response
to the stimuli. Also in accordance with the secreted protein results
and the intracellular cytokine results, IL-2, IFN-
and TNF-
expression was most strongly induced by the combination of PHA and PMA.
PHA and PMA had generally modest effects on their own. Only the
stimulation by PHA plus PMA resulted in a difference from
unstimulated which was statistically significant for TNF-
. There were broad differences in expression between individual donors.
Both the 4-h and 24-h time points resulted in increased cytokine
message. Generally, the 4-h time point was superior to the 24-h time
point, although the optimal stimulation protocol for TNF-
was the
combination of PHA and PMA at 24 h.
 |
DISCUSSION |
The detection of cytokines provides valuable information about the
nature of the host response to infection or the nature of an ongoing
inflammatory response. Because of the great power of these types of
studies, there has been interest in transplanting cytokine detection
assays to a clinical arena. Before that can be accomplished, it would
be desirable to define a type of stimulation protocol that would be
broadly applicable and would maximize the amount of information that
can be derived from a single patient sample. This study utilized three
detection methods and three different stimulation protocols in an
effort to identify one strategy from which several different types of
information could be generated. In general, 24 h of stimulation
with both PHA and PMA was the most potent stimulus. Extensive kinetic
studies were not performed to determine the individual peaks of
cytokine production using each cytokine and each methodology because
the rationale for this study was to identify a common strategy to
maximize the information from a single protocol. Nevertheless, others
have found cytokine mRNA production to peak at 4 to 8 h and
protein production to peak at 24 to 48 h (6, 8, 10, 11, 17,
22). We assayed a relatively small number of cytokines in this
study although they were chosen to be representative of those most
commonly implicated in various pathologic processes. Cytokines were
selected to represent Th1 (IL-2 and IFN-
production, Th2 (IL-4)
production, and macrophage (TNF-
) production. Therefore, it is
possible that this stimulation protocol may not be optimal for a
different set of cytokines. Nevertheless, it is likely that one could
use this stimulation protocol for most T-cell-derived cytokines.
One of the advantages of standardizing the stimulation protocol for
multiple cytokines, is that a few million cells becomes sufficient for
both secreted protein analysis, mRNA detection, and intracellular
cytokine detection. The supernatant and cells from a single stimulation
of 1 million cells are sufficient to detect five different cytokines in
the supernatant and four different cytokines from the cellular mRNA.
This has particular relevance in the pediatric population, where blood
volume has been a significant constraint on this type of analysis. The
flow cytometry requires the most cells, with 1 million cells required
for each cytokine being assayed.
The regulation of expression of different cytokines depends on the
rates of transcription, splicing, message turnover, translation, protein processing, export, and protein degradation. Each of these steps, in principle, is regulatable by different stimuli or inhibitors. It is generally believed that the most important sites of regulation are at the level of transcription, message turnover, and protein degradation. While cytokines share some general regulatory themes, the
stimuli that maximally induce expression and minimize turnover and
degradation are distinct for each cytokine. The use of PMA and PHA
together activates multiple signalling pathways, which allows for broad
stimulation of cytokines in mixed PBMC cultures (2, 13, 14).
A disadvantage of this method is that changes in the cellular
constituents of the PBMC population, such as is seen in HIV infection,
ongoing autoimmune disease, or advanced malignancies, may result in
different patterns of cytokine production that reflect the cellular
makeup of the PBMC population, not the inherent ability of the cells to
produce certain cytokines. If flow cytometry is performed, it would be
possible to characterize the cellular constituents and control for
intersample variations in cellular makeup. While bulk stimulation of
PBMC has the disadvantage of reflecting differences in cell
distribution, it has the advantage of reflecting differences due to
complex cell-cell interactions, which could be relevant for the
individual disease processes being studied.
This study demonstrates the feasibility of using a single stimulation
protocol on a single small sample of PBMCs to generate data on secreted
cytokines, intracellular cytokines, and cytokine messages. This is an
important first step in making these types of assays more applicable to
a clinical setting. It is likely that defining cytokine expression will
play an increasing role in the management of autoimmune disorders, for
example. The use of a single stimulation protocol could also be of
benefit in comparing results from different laboratories.
 |
ACKNOWLEDGMENTS |
This work was supported in part by The Children's Hospital of
Philadelphia Wallace Chair (Stuart E. Starr), the University of
Pennsylvania Center for AIDS Research (grant P30 AI45008), the REACH
project of the Adolescent Medicine HIV/AIDS Research Network (NIH U01
HD32842) and Pediatric AIDS Clinical Trials Group Core Laboratory (NIH
UO1 AI 32921).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Immunologic and
Infectious Diseases, The Children's Hospital of Philadelphia, 34th St.
and Civic Ctr. Blvd., Philadelphia, PA 19104. Phone: (215) 590-1697. Fax: (215) 590-3044. E-mail:
sullivak{at}mail.med.upenn.edu.
 |
REFERENCES |
| 1.
|
Aziz, N.,
P. Nishanian,
R. Mitsuyasu,
R. Detels, and J. L. Fahey.
1999.
Variables that affect assays for plasma cytokines and soluble activation markers.
Clin. Diagn. Lab. Immunol.
6:89-95[Abstract/Free Full Text].
|
| 2.
|
Baldari, C. T.,
G. Macchia,
A. Heguy,
M. Melli, and J. L. Telford.
1991.
Cyclosporin A blocks calcium-dependent pathways of gene activation.
J. Biol. Chem.
266:19103-19108[Abstract/Free Full Text].
|
| 3.
|
Benveniste, O.,
M. Martin,
F. Villinger, and D. Dormont.
1998.
Techniques for quantification of cytokine mRNAs.
Cytokines Cell. Mol. Ther.
4:207-214[Medline].
|
| 4.
|
Bienvenu, J. A.,
G. Monneret,
M. C. Gutowski, and N. Fabien.
1998.
Cytokine assays in human sera and tissues.
Toxicology
129:55-61[CrossRef][Medline].
|
| 5.
|
Dugue, B.,
E. Leppanen, and R. Grasbeck.
1996.
Preanalytical factors and the measurement of cytokines in human subjects.
Int. J. Clin. Lab. Res.
26:99-105[Medline].
|
| 6.
|
Esnault, S.,
N. Benbernou,
F. Lavaud,
H. C. Shin,
G. Potron, and M. Guenounou.
1996.
Differential spontaneous expression of mRNA for IL-4, IL-10, IL-13, IL-2 and interferon-gamma (IFN-gamma) in peripheral blood mononuclear cells (PBMC) from atopic patients.
Clin. Exp. Immunol.
103:111-118[CrossRef][Medline].
|
| 7.
|
Faist, E.,
M. Storck,
L. Hultner,
H. Redl,
W. Ertel,
A. Walz, and F. W. Schildberg.
1992.
Functional analysis of monocyte activity through synthesis patterns of proinflammatory cytokines and neopterin in patients in surgical intensive care.
Surgery
112:562-572[Medline].
|
| 8.
|
Fan, J.,
P. Nishanian,
E. C. Breen,
M. McDonald, and J. L. Fahey.
1998.
Cytokine gene expression in normal human lymphocytes in response to stimulation.
Clin. Diagn. Lab. Immunol.
5:335-340[Abstract].
|
| 9.
|
Feldman, M.,
P. Taylor,
E. Paleolog,
F. M. Brennan, and R. N. Maini.
1998.
Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.
Transplant. Proc.
30:4126-4127[CrossRef][Medline].
|
| 10.
|
Heijligenberg, R.,
J. A. Romijn,
M. H. Godfried,
E. Endert, and H. P. Sauerwein.
1998.
In vitro production of cytokines in whole blood versus plasma concentrations of cytokines in AIDS.
AIDS Res. Hum. Retroviruses.
14:123-127[Medline].
|
| 11.
|
Hyjek, E.,
H. W. Lischner,
T. Hyslop,
J. Bartkowiak,
M. Kubin,
G. Trinchieri, and D. Kozbor.
1995.
Cytokine patterns during progression to AIDS in children with perinatal HIV infection.
J. Immunol.
155:4060-4071[Abstract].
|
| 12.
|
Kotake, S.,
H. R. Schumacher, Jr., and R. L. Wilder.
1996.
A simple nested RT-PCR method for quantitation of the relative amounts of multiple cytokine mRNAs in small tissue samples.
J. Immunol. Methods
199:193-203[CrossRef][Medline].
|
| 13.
|
Liu, J.,
T. Sakane, and T. Tsunematsu.
1992.
The effects of FK506 and cyclosporin A on the proliferation of PHA-stimulated T cells in response to IL-2, IL-4 or IL-6.
Int. Arch. Allergy Immunol.
98:293-298[Medline].
|
| 14.
|
Mills, G. B.,
M. Hill,
M. McGill,
C. May,
J. Stanley,
D. J. Stewart,
A. Mellors, and E. W. Gelfand.
1990.
Interrelationship between signals transduced by phytohemagglutinin and interleukin 1.
J. Cell. Physiol.
142:539-551[CrossRef][Medline].
|
| 15.
|
Mira, J. P.,
A. Cariou,
F. Grall,
C. Delclaux,
M. R. Losser,
F. Heshmati,
C. Cheval,
M. Monchi,
J. L. Teboul,
F. Riche,
G. Leleu,
L. Arbibe,
A. Mignon,
M. Delpech, and J. F. Dhainaut.
1999.
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study.
JAMA
282:561-568[Abstract/Free Full Text].
|
| 16.
|
Mire-Sluis, A. R., and R. Thorpe.
1998.
Laboratory protocols for the quantitation of cytokines by bioassay using cytokine responsive cell lines.
J. Immunol. Methods
211:199-210[CrossRef][Medline].
|
| 17.
|
O'Mahony, L.,
J. Holland,
J. Jackson,
C. Feighery,
T. P. Hennessy, and K. Mealy.
1998.
Quantitative intracellular cytokine measurement: age-related changes in proinflammatory cytokine production.
Clin. Exp. Immunol.
113:213-219[CrossRef][Medline].
|
| 18.
|
Plevy, S. E.,
C. J. Landers,
J. Prehn,
N. M. Carramanzana,
R. L. Deem,
D. Shealy, and S. R. Targan.
1997.
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.
J. Immunol.
159:6276-6282[Abstract].
|
| 19.
|
Schauer, U.,
T. Jung,
N. Krug, and A. Frew.
1996.
Measurement of intracellular cytokines.
Immunol. Today
17:305-306[CrossRef][Medline].
|
| 20.
|
Sousa, A. E.,
A. F. Chaves,
M. Doroana,
F. Antunes, and R. M. M. Victorino.
1999.
Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection.
J. Immunol.
162:3718-3726[Abstract/Free Full Text].
|
| 21.
|
Tarnuzzer, R. W.,
S. P. Macauley,
W. G. Farmerie,
S. Caballero,
M. R. Ghassemifar,
J. T. Anderson,
C. P. Robinson,
M. B. Grant,
M. G. Humphreys-Beher,
L. Franzen,
A. B. Peck, and G. S. Schultz.
1996.
Competitive RNA templates for detection and quantitation of growth factors, cytokines, extracellular matrix components and matrix metalloproteinases by RT-PCR.
BioTechniques
20:670-674[Medline].
|
| 22.
|
Than, S.,
R. Hu,
N. Oyaizu,
J. Romano,
X.-P. Wang,
S. Sheikh, and S. Pahwa.
1997.
Cytokine pattern in relation to disease progression in human immunodeficiency disease virus-infected children.
J. Infect. Dis.
175:47-56[Medline].
|
| 23.
|
Wadhwa, M., and R. Thorpe.
1998.
Cytokine immunoassays: recommendations for standardisation, calibration and validation.
J. Immunol. Methods
219:1-5[CrossRef][Medline].
|
| 24.
|
Wang, A. M.,
M. V. Doyle, and D. F. Mark.
1989.
Quantitation of mRNA by the polymerase chain reaction.
Proc. Natl. Acad. Sci. USA
86:9717-9721[Abstract/Free Full Text].
|
| 25.
|
Westendorp, R. G. J.,
J. A. M. Langermans,
T. W. J. Huizenga,
A. H. Elouali,
C. L. Verweij,
D. I. Boomsma, and J. P. Vandenbrouke.
1997.
Genetic influence on cytokine production and fatal meningococcal disease.
Lancet
349:170-173[CrossRef][Medline].
|
| 26.
|
Wheeler, A. P., and G. R. Bernard.
1999.
Treating patients with severe sepsis.
N. Engl. J. Med.
340:207-214[Free Full Text].
|
Clinical and Diagnostic Laboratory Immunology, November 2000, p. 920-924, Vol. 7, No. 6
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Dheda, K., Chang, J.-S., Breen, R. A. M., Kim, L. U., Haddock, J. A., Huggett, J. F., Johnson, M. A., Rook, G. A. W., Zumla, A.
(2005). In Vivo and In Vitro Studies of a Novel Cytokine, Interleukin 4{delta}2, in Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med.
172: 501-508
[Abstract]
[Full Text]
-
Douglas, S. D., Durako, S., Sullivan, K. E., Camarca, M., Moscicki, A.-B., Wilson, C. M.
(2003). TH1 and TH2 Cytokine mRNA and Protein Levels in Human Immunodeficiency Virus (HIV)-Seropositive and HIV-Seronegative Youths. CVI
10: 399-404
[Abstract]
[Full Text]
-
Walker, D., Jason, J., Wallace, K., Slaughter, J., Whatley, V., Han, A., Nwanyanwu, O. C., Kazembe, P. N., Dobbie, H., Archibald, L., Jarvis, W. R.
(2002). Spontaneous Cytokine Production and Its Effect on Induced Production. CVI
9: 1049-1056
[Abstract]
[Full Text]